Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Kouichi Kikuchi

Shigeki Hibi

Hiroyuki Yoshimura

Mitsuo Nagai

Takayuki Hida

Katsuya Tagami

Seiichi Kobayashi

Shinya Abe

Takashi Yamanaka

Seiko Higashi

Ieharu Hishinuma

Kenji Tai

Hisashi Shibata

Makoto Okita

Yorihisa Hoshino

Naoki Tokuhara

Motohiro Soejima

Junichi Nagakawa

Makoto Asada

Norimasa Miyamoto

Aichi Ogasawara

Isao Yamatsu

Shuhei Miyazawa

Kazuo Hirota

Masanori Mizuno

Takashi Mori

Toshihiko Kaneko

Mark Spyvee

Yoshinori Takahashi

Yasushi Okamoto

Kenzo Muramoto

Takashi Sato

Boris M Seletsky

Kogyoku Shin

Heather Davis

Wanjun Zheng

Yimin Jiang

Tatsuya Yoshiuchi

André Lescarbeau

Norihito Ohi

Xiang-Yi Li

Naoki Kobayashi

Bruce Decosta

Fabian Gusovsky

Tetsuya Hirakawa

Hiromitsu Yokohama

Marc Pesant

Mutsuko Tabata

Ye Yao

Jane Daun

Lynda Tremblay

Yumiko Nagasaka

Yan (Janet) Zhao

Mitsuhiro Ino

The present invention provides compounds having formula (I): 

Deazapurines and uses thereof

As discussed above, there remains a need for the development of novel therapeutic agents useful for treating inflammatory or autoimmune and proliferative diseases. The present invention provides novel compounds of general formula (I), and pharmaceutical compositions thereof, as described generally and in classes and subclasses herein, as well as methods of making and using such compounds.

The present invention provides compounds having formula (I), wherein R, R, Rand n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally 

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof,wherein Ris a hydrogen atom, etc.; Ris a hydrogen atom, etc.; M' represents a hydrogen atom, a halogen atom or a Calkyl group; R&#x2032; represents a hydrogen atom or a Calkyl group; and W&#x2032; represents a phenyl group, pyridyl group, thienyl group, or furyl group, each being optionally substituted; and a pharmacologically acceptable salt thereof or hydrates thereof.

Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof.Wherein A, B and D are the same as or different from each other and each represents a group represented by the formula &#x2014;(CRR)&#x2014; (wherein Rand Rare the same as or different from each other and each represents a Calkyl group etc.), &#x2014;NR&#x2014; (wherein Rrepresetns hydrogen etc.) etc.; E and G are the same as or different from each other and each represents a group represented by the formula &#x2014;(CRR)&#x2014; (wherein Rand Rare the same as or different from each other and each represents hydrogen etc.; and p represents an integer of 0, 1 or 2); J represents a carbon atom or nitrogen atom, each substituted with Calkyl group optionally substituted with a halogen atom, etc.; K and L are the same as or different from each other and each represents carbon atom or nitrogen atom; M means hydrogen, a halogen atom, an optionally substituted Calkyl group etc.; and the partial structuremeans a single or double bond.

Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof,wherein

Described is a heterocycle-containing carboxylic acid derivative represented by the following formula (I):wherein A represents, for example, a heteroaryl group which contains at least one nitrogen atom and may have a substituent, B represents, for example, a heteroarylene group, a &#x2014;CONH&#x2014; group or a group represented by the formula &#x2014;CR&#x2550;CR&#x2014; in which Rand Rrepresents H, a lower alkyl group or the like, D represents an arylene group, a heteroarylene group or the like, n1 stands for 0 or 1, M represents, for example, a hydroxyl group or a lower alkoxy group; or a physiologically acceptable salt thereof. As a retinoic-related compound replacing retinoic acid, it permits the provision of a preventive and/or therapeutic for various diseases.

Heterocycle-containing carboxylic acid derivative and drug containing the same

Mono- or polyenic carboxylic acid derivatives

Carboxylic acid derivatives having fused rings

Described is a heterocycle-containing carboxylic acid derivative represented by the following formula (I):

To provide novel compounds relating to retinoid which can substitute for retinoic acid used for preventing and treating several diseases and having antagonism against retinoid. Heterocyclic compounds represented by the general formula (1-I) or physiologically acceptable salts thereof:

Fused-ring carboxylic acid derivatives

Growing community of inventors

Tsuchiura, Japan

Kouichi Kikuchi